Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James S Floyd

Showing results (1-10 of 138) with videos related to

Pageof 14
Sort By:
Heart (British Cardiac Society)|July 26, 2014
β-blockers for secondary prevention in stable coronary artery disease: can observational studies provide valid answers?James S Floyd
JAMA Internal Medicine|July 16, 2014
The potential risks of expedited approval of drugs for acute bacterial infectionsJames S Floyd, Bruce M Psaty
The New England Journal of Medicine|December 17, 2010
Trial of lorcaserin for weight managementJames S Floyd, Susan R Heckbert
Diabetes Care|December 8, 2016
The Application of Genomics in Diabetes: Barriers to Discovery and ImplementationJames S Floyd, Bruce M Psaty
Archives of Internal Medicine|August 29, 2012
Observational comparative effectiveness studies of drug therapies: high-quality answers or important clinical questions?: comment on "Comparative effectiveness of 2 β-blockers in hypertensive patients"James S Floyd, Bruce M Psaty
Archives of Internal Medicine|June 30, 2010
Prasugrel as a potential cancer promoter: review of the unpublished dataJames S Floyd, Victor L Serebruany
JAMA|March 26, 2009
The role of tax reform in health care reformJames S Floyd, Sidney M Wolfe, Marcia Angell
Current Atherosclerosis Reports|November 7, 2016
Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises UnmetJames H Flory, Jenny K Ukena, James S Floyd
Pharmacoepidemiology and Drug Safety|July 23, 2009
Case series of liver failure associated with rosiglitazone and pioglitazoneJames S Floyd, Elizabeth Barbehenn, Peter Lurie, et al.
Epidemiology (Cambridge, Mass.)|November 30, 2021
The Authors RespondJames S Floyd, Susan Gruber, David S Carrell, et al.
Pageof 14

Showing results (1-10 of 138) with videos related to

Sort By:
Pageof 14
Heart (British Cardiac Society)|July 26, 2014
β-blockers for secondary prevention in stable coronary artery disease: can observational studies provide valid answers?James S Floyd
JAMA Internal Medicine|July 16, 2014
The potential risks of expedited approval of drugs for acute bacterial infectionsJames S Floyd, Bruce M Psaty
The New England Journal of Medicine|December 17, 2010
Trial of lorcaserin for weight managementJames S Floyd, Susan R Heckbert
Diabetes Care|December 8, 2016
The Application of Genomics in Diabetes: Barriers to Discovery and ImplementationJames S Floyd, Bruce M Psaty
Archives of Internal Medicine|August 29, 2012
Observational comparative effectiveness studies of drug therapies: high-quality answers or important clinical questions?: comment on "Comparative effectiveness of 2 β-blockers in hypertensive patients"James S Floyd, Bruce M Psaty
Archives of Internal Medicine|June 30, 2010
Prasugrel as a potential cancer promoter: review of the unpublished dataJames S Floyd, Victor L Serebruany
JAMA|March 26, 2009
The role of tax reform in health care reformJames S Floyd, Sidney M Wolfe, Marcia Angell
Current Atherosclerosis Reports|November 7, 2016
Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises UnmetJames H Flory, Jenny K Ukena, James S Floyd
Pharmacoepidemiology and Drug Safety|July 23, 2009
Case series of liver failure associated with rosiglitazone and pioglitazoneJames S Floyd, Elizabeth Barbehenn, Peter Lurie, et al.
Epidemiology (Cambridge, Mass.)|November 30, 2021
The Authors RespondJames S Floyd, Susan Gruber, David S Carrell, et al.
Pageof 14